Compare OPHC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPHC | MAIA |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 79.0M |
| IPO Year | 2012 | 2022 |
| Metric | OPHC | MAIA |
|---|---|---|
| Price | $5.73 | $1.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | 37.2K | ★ 834.8K |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17,095.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $0.87 |
| 52 Week High | $5.90 | $3.19 |
| Indicator | OPHC | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 58.96 |
| Support Level | $5.40 | $1.24 |
| Resistance Level | $5.90 | $1.57 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 55.26 | 80.43 |
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.